# C_2007226EN.01002001.xml

| 26.9.2007 | EN | Official Journal of the European Union | C 226/20 |
| --- | --- | --- | --- |

26.9.2007

EN

Official Journal of the European Union

C 226/20

---

Prior notification of a concentration

(Case COMP/M.4865 — Siemens/Dade Behring)

(Text with EEA relevance)

(2007/C 226/09)

| 1. | On 20 September 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the German undertaking Siemens AG (‘Siemens’, Germany) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Dade Behring Inc. (‘Dade Behring’, USA) by way of a purchase of shares. |
| --- | --- |

1.

On 20 September 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the German undertaking Siemens AG (‘Siemens’, Germany) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Dade Behring Inc. (‘Dade Behring’, USA) by way of a purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | for Siemens: diversified company active in various manufacturing, technology and services business activities, including medical systems. Within the latter, Siemens is active in vitro diagnostics through its subsidiary Diagnostic Products Corporation, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Siemens: diversified company active in various manufacturing, technology and services business activities, including medical systems. Within the latter, Siemens is active in vitro diagnostics through its subsidiary Diagnostic Products Corporation,

in vitro

| — | for Dade Behring: development, manufacture and sales of in vitro diagnostic systems for hospitals, medical laboratories and physicians' offices. |
| --- | --- |

—

for Dade Behring: development, manufacture and sales of in vitro diagnostic systems for hospitals, medical laboratories and physicians' offices.

in vitro

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4865 — Siemens/Dade Behring, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Bruxelles/Brussel |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4865 — Siemens/Dade Behring, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Bruxelles/Brussel

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---